Clinical Trials Browser

Interventional × Has results × Fanconi Anemia, Complementation Group D1 × Clear all

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Phase 2 Completed

265 enrolled 25 charts 1 FDA

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00494234 2024-01-19

ICEBERG 1

Phase 2 Completed

54 enrolled 17 charts

BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

Phase 2 Completed

97 enrolled 22 charts

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Phase 1 Completed

113 enrolled 39 charts

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma